Prostate cancer

Current Care Summary
Working group appointed by the Finnish Medical Society Duodecim and the Finnish Urological Association

Current Care Guideline «Eturauhassyöpä»1 and Summary «Eturauhassyöpä»2 in Finnish

The annual incidence of prostate cancer (PC) in Finland was 4 700 (year 2010). The treatment decision is made together with the patient according to patient characteristics, cancer classification and recurrence risk rate. For local PC, recommended treatment is active surveillance, radical prostatectomy, radiation (+/- hormonal) therapy or hormonal therapy. Metastatic PC patients are treated with hormonal therapy. The aim for castrate resistant metastatic PC patients is to improve quality of life and relieve symptoms. The 5-year survival rate is 93 %. Follow-up is tailored individually. Population based PSA screening is not recommended.

Sirpa Aaltomaa (chair)

Pekka Jousilahti

Vesa Kataja

Merja Korpela

Paula Kujala

Matti Laato

Paula Lindholm

Mika Matikainen

Antti Rannikko

Raija Sipilä

Teuvo Tammela